De-Ming Yang

De-Ming Yang

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YTYung-Fang Tu
Yung-Fang Tu
CCChianshiu Chien
Chianshiu Chien
AYAliaksandr Yarmishyn
Aliaksandr Yarmishyn
YLYi-Ying Lin
Yi-Ying Lin
YLYung-Hung Luo
Yung-Hung Luo
Shih-Hwa ChiouShih-Hwa Chiou
Shih-Hwa Chiou
The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.

15 April 2012 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
YKYi-Yun Kao
Yi-Yun Kao
TCTsun-Jen Cheng
Tsun-Jen Cheng
De-Ming YangDe-Ming Yang
De-Ming Yang
CWChin-Tien Wang
Chin-Tien Wang
YCYin-Mei Chiung
Yin-Mei Chiung
PLPei-Shan Liu
Pei-Shan Liu

1 May 2012 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
KTKun-Ling Tsai
Kun-Ling Tsai
YHYi-Hsiang Huang
Yi-Hsiang Huang
CKChung-Lan Kao
Chung-Lan Kao
De-Ming YangDe-Ming Yang
De-Ming Yang
Hsin-Chen LeeHsin-Chen Lee
Hsin-Chen Lee
SCShih-Hwa Chiou
Shih-Hwa Chiou

1 August 2014 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
YCYun-Ching Chang
Yun-Ching Chang
WCWei-Chao Chang
Wei-Chao Chang
KHKuo-Hsuan Hung
Kuo-Hsuan Hung
De-Ming YangDe-Ming Yang
De-Ming Yang
YCYung-Hsin Cheng
Yung-Hsin Cheng
SCShih-Jen Chen
Shih-Jen Chen
Age-related macular degeneration (AMD) is one retinal aging process that may lead to irreversible vision loss in the elderly. Its pathogenesis remains unclear, but oxidative stress inducing retinal pigment epithelial (RPE) cells damage is perhaps responsible for the aging sequence of retina and may play an important role in macular degeneration. In this study, we have reprogrammed T cells from patients with dry type AMD into induced pluripotent stem cells (iPSCs) via integration-free episomal vectors and differentiated them into RPE cells that were used as an expandable platform for investigating pathogenesis of the AMD and in-vitro drug screening. These patient-derived RPEs with the AMD-associated background (AMD-RPEs) exhibited reduced antioxidant ability, compared with normal RPE cells. Among several screened candidate drugs, curcumin caused most significant reduction of ROS in AMD-RPEs. Pre-treatment of curcumin protected these AMD-RPEs from H2O2-induced cell death and also increased the cytoprotective effect against the oxidative stress of H2O2 through the reduction of ROS levels. In addition, curcumin with its versatile activities modulated the expression of many oxidative stress-regulating genes such as PDGF, VEGF, IGFBP-2, HO1, SOD2, and GPX1. Our findings indicated that the RPE cells derived from AMD patients have decreased antioxidative defense, making RPE cells more susceptible to oxidative damage and thereby leading to AMD formation. Curcumin represented an ideal drug that can effectively restore the neuronal functions in AMD patient-derived RPE cells, rendering this drug an effective option for macular degeneration therapy and an agent against aging-associated oxidative stress.

1 June 2003 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ALAnya M.Y. Lin
Anya M.Y. Lin
SFS.F. Fan
S.F. Fan
De-Ming YangDe-Ming Yang
De-Ming Yang
LHL.L. Hsu
L.L. Hsu
JYJames Chih-Hsin Yang
James Chih-Hsin Yang

1 March 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Yung-Luen YuYung-Luen Yu
Yung-Luen Yu
RCRuey-Hwang Chou
Ruey-Hwang Chou
LCLing-Tzu Chen
Ling-Tzu Chen
WSWoei-Cherng Shyu
Woei-Cherng Shyu
SHSu-Ching Hsieh
Su-Ching Hsieh
MHMien-Chie Hung
Mien-Chie Hung
Enhancer of zeste homolog 2 (EZH2) regulates stem cells renewal, maintenance, and differentiation into different cell lineages including neuron. Changes in intracellular Ca(2+) concentration play a critical role in the differentiation of neurons. However, whether EZH2 modulates intracellular Ca(2+) signaling in regulating neuronal differentiation from human mesenchymal stem cells (hMSCs) still remains unclear. When hMSCs were treated with a Ca(2+) chelator or a PLC inhibitor to block IP(3)-mediated Ca(2+) signaling, neuronal differentiation was disrupted. EZH2 bound to the promoter region of PIP5K1C to suppress its transcription in proliferating hMSCs. Interestingly, knockdown of EZH2 enhanced the expression of PIP5K1C, which in turn increased the amount of PI(4,5)P(2), a precursor of IP(3), and resulted in increasing the intracellular Ca(2+) level, suggesting that EZH2 negatively regulates intracellular Ca(2+) through suppression of PIP5K1C. Knockdown of EZH2 also enhanced hMSCs differentiation into functional neuron both in vitro and in vivo. In contrast, knockdown of PIP5K1C significantly reduced PI(4,5)P(2) contents and intracellular Ca(2+) release in EZH2-silenced cells and resulted in the disruption of neuronal differentiation from hMSCs. Here, we provide the first evidence to demonstrate that after induction to neuronal differentiation, decreased EZH2 activates the expression of PIP5K1C to evoke intracellular Ca(2+) signaling, which leads hMSCs to differentiate into functional neuron lineage. Activation of intracellular Ca(2+) signaling by repressing or knocking down EZH2 might be a potential strategy to promote neuronal differentiation from hMSCs for application to neurological dysfunction diseases.